Hemophilia B Christmas Disease Factor IX Deficiency

Slide 1 · Hemophilia B

Christmas disease • Factor IX deficiency

Inheritance, mechanism, bleeding phenotype, diagnosis and therapy

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Trace the role of factor IX in formation of a stable fibrin clot.

Explain how F9 defects produce an X-linked bleeding disorder.

Interpret the characteristic screening and specific factor-assay findings.

Distinguish hemophilia B from hemophilia A and platelet/vWF disorders.

Relate factor IX replacement and gene transfer to their target mechanisms.

Slide 3 · An initial diagnostic problem

CONSTRUCTED TEACHING VIGNETTE

A young patient develops a painful swollen knee after minor physical stress.

Previous dental extraction was followed by unexpectedly prolonged bleeding.

The screening tests show prolonged PTT with normal PT.

Which component of hemostasis should be investigated first?

Slide 4 · Primary and secondary hemostasis

Primary hemostasis

Platelet adhesion at exposed matrix

Platelet activation and aggregation

Initial platelet plug

Secondary hemostasis

Coagulation-factor activation

Thrombin generation

Fibrin reinforcement of the plug

Hemophilia B mainly compromises fibrin reinforcement.

Slide 5 · Locate factor IX in hemostasis

Vascular injury

Coagulation activation

Factor IX–dependent amplification

Stable fibrin clot

Factor IX deficiency weakens secondary hemostasis despite platelet-plug formation.

Slide 6 · The phenotype of coagulation-factor deficiency

Large ecchymoses and hematomas are typical after trauma.

Bleeding may continue after a laceration or surgical procedure.

Gastrointestinal, urinary-tract and joint hemorrhage may occur.

The deep-tissue pattern contrasts with characteristic platelet-type petechiae.

Slide 7 · Hemophilia B: Disease definition

Inherited factor IX deficiency or dysfunction impairs coagulation and produces a variable bleeding tendency.

F9 is the affected factor-encoding gene.

Inheritance is classically X-linked recessive.

Severe disease closely resembles factor VIII deficiency.

Slide 8 · Why it is called Christmas disease

“Christmas disease” is another name for hemophilia B.

The name comes from the surname of the first identified patient.

It is unrelated to the Christmas holiday.

The mechanistically informative designation is factor IX deficiency.

Slide 9 · From the F9 gene to impaired hemostasis

F9 gene variant

Reduced FIX amount or activity

Impaired factor X activation

Insufficient stable clot formation

Distinct mutations converge on impaired factor IX function.

Slide 10 · Factor IX is a coagulation component

Factor IX acts in the coagulation-factor network, not as a platelet receptor.

Activated factor IX functions with factor VIIIa to activate factor X.

This reaction supplies an important amplification step in vivo.

A functional deficiency therefore alters secondary hemostasis.

Slide 11 · Physiological initiation reaches factor IX

Tissue factor exposure

Tissue factor–VIIa

Factor IX → IXa

Assembly with factor VIIIa

In vivo, tissue factor–VIIa is an important activator of factor IX.

Slide 12 · Factor IXa and factor VIIIa cooperate

Factor IXa

Activated coagulation enzyme

Participates directly in factor X activation

Deficient or dysfunctional in hemophilia B

Factor VIIIa

Coagulation cofactor

Supports IXa-mediated factor X activation

Deficient or dysfunctional in hemophilia A

Different deficient partners affect the same factor X–activating reaction.

Slide 13 · The factor X activation step

Factor IXa + VIIIa

Factor X activation

Factor Xa generation

Thrombin-generating pathway

The IXa–VIIIa complex is a major factor X activator in vivo.

Slide 14 · How IX deficiency reduces thrombin

Reduced IX activity

Impaired factor Xa formation

Less efficient thrombin generation

Inadequate fibrin stabilization

This is a pathway-level explanation of the bleeding diathesis, not a measured patient response.

Slide 15 · Thrombin is the central amplifier

Thrombin converts soluble fibrinogen into fibrin.

It contributes to the activation of additional coagulation cofactors.

It promotes platelet activation and factor XIII–dependent fibrin cross-linking.

Insufficient amplification compromises clot stability.

Slide 16 · From fibrinogen to stable fibrin

Factor Xa generation

Thrombin generation

Fibrinogen → fibrin

Cross-linked fibrin mesh

A defect upstream of thrombin can undermine the final stabilizing fibrin structure.

Slide 17 · Why platelet plugs do not solve IX deficiency

Platelet phase may form

Adhesion to matrix can occur

Aggregates initially obstruct injured vessels

Platelet number is not the defining defect

Fibrin phase is inadequate

Reduced factor IX function

Deficient thrombin amplification

Less stable secondary hemostatic plug

Normal primary events do not guarantee durable hemostasis.

Slide 18 · An integrated pathogenesis model

Inherited F9 defect

Impaired IXa–VIIIa activity

Reduced fibrin stabilization

Deep/prolonged bleeding

Genotype, molecular dysfunction and clinical phenotype form a linked causal chain.

Slide 19 · A broad mutational spectrum

A wide range of causative mutations in F9.

Different variants can impair synthesis or function of the factor IX protein.

Mutation heterogeneity contributes to the variable clinical phenotype.

The genetic label alone does not replace a functional factor assay.

Slide 20 · Quantitative and qualitative FIX abnormalities

Quantitative loss

Less circulating functional factor IX

Lower activity can reflect lower protein amount

Result: Inadequate IX-dependent activation

Qualitative loss

Protein can still be present

Its coagulation activity is impaired

Result: Antigen and activity may be discordant

Functional activity, not protein presence alone, determines clotting contribution.

Slide 21 · Factor IX protein can be nonfunctional

In approximately 15% of patients, factor IX protein is present but lacks normal function.

A detectable protein concentration does not guarantee activity.

The defect can lie in molecular performance rather than complete absence.

Diagnosis must assess factor IX function.

Slide 22 · Activity versus protein concentration

Functional FIX activity

Assesses ability to contribute to clot formation

Essential for definitive factor-specific diagnosis

Can be low even when protein is present

FIX antigen / protein

Indicates circulating protein amount

Does not by itself prove coagulation function

Discordance suggests qualitative dysfunction

The textbook explicitly notes functionally inactive but present factor IX in some patients.

Slide 23 · X-linked recessive inheritance

A pathogenic F9 variant on the X chromosome produces the classical inheritance pattern of hemophilia B.

Hemizygous males carrying the variant are commonly affected.

Heterozygous females can transmit the variant.

Family sex pattern helps support—but does not establish—the diagnosis.

Slide 24 · Carrier mother: Illustrative segregation

Maternal X

Paternal contribution

Offspring genotype

Expected interpretation

X (unaffected)

Y

XY

Son without familial variant

X* (F9 variant)

Y

X*Y

Affected son

X (unaffected)

X

XX

Daughter without familial variant

X* (F9 variant)

X

X*X

Heterozygous daughter

Each listed combination is equally likely in this simple Mendelian example; * denotes the familial F9 variant.

Slide 25 · Affected father: X-linked transmission

To sons

Father contributes a Y chromosome.

His affected X is not passed to sons.

No father-to-son transmission of the paternal X variant.

To daughters

Father contributes his affected X chromosome.

All daughters inherit that paternal X.

With a non-carrier mother, daughters are heterozygous.

The other parent’s genotype must be specified before assigning risk.

Slide 26 · Interpreting females in an X-linked disorder

Classical X-linked recessive inheritance primarily affects hemizygous males.

A heterozygous state does not automatically exclude symptomatic bleeding.

X-chromosome inactivation can modify expression of an X-linked factor deficiency.

Phenotypic evaluation takes precedence over a simplistic “carrier = asymptomatic” rule.

Slide 27 · Why clinical severity varies

A spectrum of hemophilia B severity.

Different F9 defects can leave different amounts of functional FIX.

Patients may present after a major hemostatic challenge or earlier with severe bleeding.

Severity should be interpreted using measured factor activity and clinical history.

Slide 28 · Severe and less severe expression

Severe functional deficiency

Potentially substantial hemorrhage

Clinical phenotype resembles severe hemophilia A

Recurrent joint bleeding is possible

Residual functional activity

Bleeding may be less conspicuous

Clinical challenge can unmask disease

A family history can direct testing

The source supplies a qualitative severity spectrum; No FIX thresholds are assigned here.

Slide 29 · Why hemophilia A and B can look identical

Factor VIIIa and factor IXa participate in the same factor X activation step.

Severe loss of either partner compromises the same amplification reaction.

Deep hemorrhage and hemarthroses therefore overlap clinically.

Factor-specific tests are required to distinguish the diseases.

Slide 30 · A delayed postprocedural bleed

Tooth extraction

Initial hemostatic response

Inadequate fibrin reinforcement

Persistent or recurrent oozing

Prolonged bleeding after dental work is a classic clue to coagulation-factor deficiency.

Slide 31 · Ecchymoses: A factor-deficiency clue

Large posttraumatic ecchymoses feature in coagulation-factor disorders.

The observed bruise reflects leakage of blood into tissue.

Size and persistence may be out of proportion to the apparent injury.

A deep-bleeding history should prompt coagulation testing.

Slide 32 · Hematomas: Deep-tissue hemorrhage

A hematoma is a collection of blood within tissue or an anatomical space.

Clotting-factor deficiencies predispose to sizable hematomas after trauma.

Deep bleeding may be clinically more important than visible skin changes.

Bleeding site and severity govern urgency of assessment.

Slide 33 · Bleeding after procedures

Surgery and dental extraction stress the coagulation system.

Persisting bleeding after an apparently minor procedure is diagnostically informative.

Asking specifically about prior procedures can reveal a lifelong bleeding tendency.

A normal-looking initial platelet response does not exclude hemophilia B.

Slide 34 · Hemarthrosis: Why joints matter

Minor mechanical stress

Bleeding into joint space

Pain and swelling

Restricted joint function

Joint bleeding is particularly characteristic of severe coagulation-factor deficiency.

Slide 35 · Recurrent joint hemorrhage has consequences

Repeated hemarthroses

Chronic joint injury

Progressive deformity

Potential disability

Robbins explicitly links recurrent joint hemorrhage to deformity in the hemophilia phenotype.

Slide 36 · Musculoskeletal bleeding pattern

Joints are a major site of spontaneous or minimally provoked hemorrhage.

Muscle and deep-tissue bleeding may occur in severe inherited factor deficiency.

Symptoms may be disproportionate to visible cutaneous findings.

The distribution helps distinguish the disorder from a purely platelet-type bleed.

Slide 37 · Gastrointestinal and urinary tract hemorrhage

Gastrointestinal bleeding

Recognized site in clotting-factor deficiency

Can be clinically significant even without skin petechiae

Requires site-specific clinical evaluation

Urinary tract bleeding

Another recognized deep-system bleeding site

Hematuria may reveal the bleeding tendency

Do not infer the anatomical source from coagulation results alone

Coagulation disorders can cause internal as well as posttraumatic bleeding.

Slide 38 · Central nervous system hemorrhage

Bleeding within the central nervous system is a potentially catastrophic manifestation of severe hemophilia.

CNS sites among characteristic severe hemophilia bleeds.

Neurologic symptoms require urgent clinical assessment.

The coagulation-factor diagnosis does not localize the hemorrhage.

Slide 39 · Why petechiae are not the classic pattern

Platelet-type bleeding

Petechiae and superficial mucocutaneous manifestations

Often reflects number or function of platelets

Primary hemostatic plug is defective

Factor IX deficiency

Large bruises, hematomas, hemarthroses

Fibrin reinforcement is defective

Petechiae are characteristically absent

A negative finding—no petechiae—can be useful when interpreting a deep-bleeding syndrome.

Slide 40 · Hemophilia B versus hemophilia A

Feature

Hemophilia B

Hemophilia A

Affected factor

IX

VIII

Primary gene involved

F9

F8

Inheritance

X-linked recessive

X-linked recessive

Functional lesion

IXa partner of tenase

VIIIa cofactor of tenase

Typical laboratory pattern

Prolonged PTT; Normal PT

Prolonged PTT; Normal PT

Confirmation

Specific FIX activity assay

Specific FVIII activity assay

Slide 41 · Hemophilia B versus von Willebrand disease

Feature

Hemophilia B

Von Willebrand disease

Main molecular target

Factor IX

Von Willebrand factor

Principal defect

Coagulation amplification

Platelet adhesion ± factor VIII stability

Bleeding pattern

Deep bleeding / hemarthrosis

Often mucocutaneous

Prolonged PTT?

Typical

Possible, especially with low FVIII

Diagnostic approach

FIX-specific assay

VWF-related studies

Slide 42 · Screening tests ask different questions

PT

Evaluates an alternative screening pathway

Typically normal in hemophilia B

Normal result does not exclude a coagulation disorder

PTT / aPTT

Probes intrinsic/common coagulation factors

Typically prolonged in hemophilia B

Abnormal result warrants factor-specific evaluation

Use the pair of tests as a pattern, not as a definitive factor diagnosis.

Slide 43 · The classic hemophilia B laboratory pattern

Prolonged partial thromboplastin time (PTT) with normal prothrombin time (PT).

The abnormal screening pathway includes factor IX activity.

PT can remain normal despite serious IX deficiency.

The pattern is suggestive, not specific to hemophilia B.

Slide 44 · Interpret an isolated prolonged PTT

History of bleeding

Prolonged PTT + normal PT

Consider intrinsic-pathway defect

Specific factor assays

The final step differentiates factor IX from factor VIII and other possible causes.

Slide 45 · What a screening PTT cannot prove

PTT does not uniquely identify factor IX deficiency.

Hemophilia A also prolongs PTT while leaving PT normal.

Other abnormalities can affect the same screening test.

A specific factor IX assay is required to assign the diagnosis.

Slide 46 · Definitive laboratory identification

Measurement of factor IX activity establishes the specific deficient factor.

Pair the result with bleeding history and the screening profile.

A FIX assay differentiates hemophilia B from the clinical mimic hemophilia A.

A protein assay alone can miss a qualitative FIX defect.

Slide 47 · Diagnostic workflow for suspected hemophilia B

Deep bleeding history

PT normal / PTT prolonged

Assay factor IX activity

Integrate genetic and clinical context

Interpret results in context; A screening result alone is never the final diagnosis.

Slide 48 · A qualitative factor IX variant: Diagnostic trap

The factor IX molecule may be detectable despite being nonfunctional.

An antigen measurement can be reassuring for the wrong reason.

Functional measurement resolves the clinically important question.

Discordance between antigen and activity is mechanistically informative.

Slide 49 · Inherited single-factor versus acquired deficits

Hemophilia B

Inherited factor IX-specific abnormality

Classically X-linked recessive pattern

May present with long-standing bleeding history

Acquired factor deficiency

Commonly involves multiple coagulation factors

May arise from deficient synthesis or consumption

Clinical context is frequently systemic

The distinction is etiologic; Laboratory evaluation determines the actual mechanism.

Slide 50 · Vitamin K deficiency in the differential

Vitamin K is needed for synthesis of factors II, VII, IX and X.

Thus a low FIX-related pathway contribution need not imply inherited F9 disease.

Several factor activities can be involved in vitamin K deficiency.

Clinical context and factor-specific evaluation prevent misclassification.

Slide 51 · Liver disease in the differential

Many coagulation proteins are synthesized in the liver.

Severe parenchymal disease may reduce synthesis of several factors.

A multiple-factor synthesis problem differs from an inherited single-factor F9 defect.

Do not assign hemophilia B solely from prolonged coagulation screening.

Slide 52 · Consumption coagulopathy is different

Hemophilia B

Primary defect in factor IX

Inherited bleeding predisposition

No defining microvascular-thrombus process

Disseminated intravascular coagulation

Acquired excessive coagulation activation

Consumption of platelets and multiple factors

Microvascular thrombosis and/or bleeding

DIC is a separate disorder, not an alternative name for factor IX deficiency.

Slide 53 · A prolonged PTT can occur in vWF disease

Von Willebrand factor stabilizes factor VIII in plasma.

Marked vWF deficiency can therefore lower FVIII activity.

Reduced FVIII may prolong PTT and resemble a hemophilia screen.

Assess factor identity and clinical bleeding pattern before concluding hemophilia B.

Slide 54 · Integrate phenotype, screen and assay

Finding

Supports

Cannot alone establish

Deep hematomas / hemarthroses

Coagulation-factor phenotype

Specific deficient factor

PT normal; PTT prolonged

Intrinsic-pathway factor defect

Factor IX rather than factor VIII

Reduced FIX activity

Hemophilia B mechanism

Inheritance without history/genetics

FIX protein detected

Protein synthesis/presence

Normal FIX function

Slide 55 · Factor IX replacement

Infusion of recombinant factor IX supplies the deficient coagulation component.

Replacement targets the missing or ineffective protein function.

The rationale is restoration of IX-dependent factor X activation.

Recombinant FIX infusion as historical standard therapy.

Slide 56 · Mechanism of recombinant FIX treatment

Administer recombinant FIX

Functional circulating factor IX

Restore IXa–VIIIa reaction

Improve fibrin-forming capacity

The therapeutic target is the specific defective clotting factor.

Slide 57 · What factor replacement does—and does not—change

Recombinant factor IX treats the coagulation defect at the protein level.

Its mechanism bypasses the need to correct the underlying F9 DNA variant.

Clinical delivery and monitoring are distinct from establishing the diagnosis.

No dose, schedule or outcome estimate is inferred from the source passage.

Slide 58 · Gene therapy: A different intervention level

A one-time recombinant viral infusion can deliver a factor IX coding sequence to hepatocytes.

Approval of a gene therapy for hemophilia B.

The aim is hepatic production of functional factor IX.

This approach acts at the gene-delivery level rather than repeated protein provision.

Slide 59 · Gene transfer to hepatocytes

Recombinant viral vector

Delivery of FIX coding sequence

Hepatocyte expression

Circulating functional FIX

Original conceptual mechanism—not a patient or viral particle micrograph.

Slide 60 · Protein replacement versus gene transfer

Recombinant FIX infusion

Delivers factor IX protein

Directly addresses the circulating deficiency

Does not replace the defective inherited allele

FIX gene transfer

Delivers a coding sequence to hepatocytes

Aims for endogenous factor IX production

One-time administration

Both strategies target the same coagulation function at different biological levels.

Slide 61 · Avoid overstating gene-therapy claims

A factor IX gene therapy has been approved.

It describes the use of a recombinant virus to deliver the FIX coding sequence.

It does not provide universal eligibility, dosing or long-term outcome estimates here.

Treatment selection requires current specialist guidance beyond this source excerpt.

Slide 62 · Clinical application: Hemophilia A or B?

CONSTRUCTED TEACHING VIGNETTE

A patient has large bruises, recurrent joint bleeding and prolonged PTT.

The PT is normal.

Factor VIII activity is preserved, while factor IX activity is reduced.

Which disease is supported, and which result identifies it?

Slide 63 · Case resolution: Identify the deficient partner

Hemophilia B

The deep-bleeding pattern is consistent with coagulation-factor deficiency.

The prolonged PTT / normal PT pattern localizes the screening abnormality.

Low factor IX activity differentiates hemophilia B from hemophilia A.

Slide 64 · Clinical application: Protein without function

CONSTRUCTED TEACHING VIGNETTE

An individual has a typical hemophilia bleeding history.

Factor IX protein is measurable in plasma.

The factor IX functional assay shows markedly impaired activity.

Why does a detectable FIX protein not exclude the diagnosis?

Slide 65 · Case resolution: Qualitative FIX dysfunction

The protein may be present yet functionally defective.

This pattern in approximately 15% of hemophilia B patients.

An activity assay interrogates the clinically relevant clotting function.

Antigen and activity answer different diagnostic questions.

Slide 66 · A five-part diagnostic synthesis

Disease mechanism

F9 variant: Quantitative or qualitative FIX defect

IXa–VIIIa reaction fails to amplify factor X

Less effective thrombin and fibrin generation

Clinical identification

Deep hemorrhage, hematomas, hemarthroses

Prolonged PTT with normal PT

Low functional factor IX establishes deficient factor

Biology and laboratory interpretation should converge.

Slide 67 · Five distinctions to retain

Hemophilia B is factor IX deficiency; A is factor VIII deficiency.

Both disrupt the same major factor X activation step.

X-linked recessive transmission explains the typical family pattern.

PTT is prolonged while PT is normal—but this is not specific.

Recombinant FIX and hepatocyte-directed gene transfer act at different levels.

Slide 68 · Primary source and chapter context

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th edition (2026).

Related textbook discussions: abnormalities of clotting factors, hemophilia A, von Willebrand disease and general principles of hemostasis.

The factor IXa–VIIIa complex and its role in factor X activation provide the central mechanistic connection.